Safety and Effectiveness of Empagliflozin/Linagliptin FDC in Uncontrolled T2DM Patients with COVID-19 Infection

被引：0
|
作者：
Sengupta, Asoktaru
机构：
来源：
DIABETES | 2023年 / 72卷
关键词：
D O I：
10.2337/db23-1812-PUB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1812-PUB
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2014, 63 : A278 - A278
  • [32] A SYSTEMATIC LITERATURE REVIEW TO IDENTIFY CLINICAL DRIVERS IN COST-EFFECTIVENESS ANALYSES IN T2DM PATIENTS UNCONTROLLED ON CURRENT THERAPIES
    Afonso, M.
    Gupta, J.
    Kamra, S.
    Jasso-Mosqueda, J.
    VALUE IN HEALTH, 2016, 19 (07) : A674 - A674
  • [33] INDIRECT COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN COMPARED TO CANAGLIFLOZIN FOR PATIENTS WITH T2DM AND CARDIOVASCULAR DISEASE IN THE SPANISH NATIONAL HEALTH SERVICE
    Carrasco Perez, M.
    Male, N.
    Serra Burriel, M.
    Pfarr, E.
    Kansal, A.
    VALUE IN HEALTH, 2018, 21 : S130 - S130
  • [34] Efficacy and Safety of Empagliflozin (EMPA) in Younger, Overweight/Obese Patients with Type 2 Diabetes (T2DM) with HbA1c ≥8%
    Merker, Ludwig
    Lund, Soren S.
    Hantel, Stefan
    Salsali, Afshin
    Kim, Gabriel
    Broedl, Uli C.
    Woerle, Hans J.
    Hach, Thomas
    DIABETES, 2014, 63 : A280 - A281
  • [35] Safety and Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus (T2DM) in South Korea
    Kim, Hun-Sung
    Min, Kyungwan
    Kim, Sang Soo
    Kim, Eun Sook
    Chung, Yoon-Sok
    Chung, Choon H.
    Yun, Jae-Seung
    Kim, Won
    Kim, Dong Han
    Yoo, Soon Jib
    DIABETES, 2024, 73
  • [36] The Effect of Combination Therapy of Degludec and Liraglutide in Hospitalized Patients with Uncontrolled Type 2 Diabetes (T2DM)
    Akiyama, Tomoaki
    Yamada, Masayo
    Katsuragawa, Sho
    Terui, Sakiko
    Minami, Taichi
    Terauchi, Yasuo
    DIABETES, 2017, 66 : A295 - A295
  • [37] Results of Randomized Double Blind Phase III trial of FDC of Remogliflozin Etabonate and Teneligliptin in T2DM patients
    Balamurgan, R.
    Mohan, B.
    Kodgule, R.
    Tandon, M.
    Pendse, A.
    Khaladkar, K.
    Sharath, R.
    Katare, S.
    Suryawanshi, S.
    Barkate, H.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [38] Empagliflozin Monotherapy for 12 Weeks Improves Glycemic Control in Japanese Patients With Type 2 Diabetes (T2DM)
    Kadowaki, Takashi
    Haneda, Masakazu
    Inagaki, Nobuya
    Taniguchi, Atsushi
    Sakamoto, Masashi
    Koiwai, Kazuki
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2013, 62 : A297 - A298
  • [39] Evening Oral Insulin (ORMD-0801) Glycemic Effects in Uncontrolled T2DM Patients
    Eldor, Roy
    Fleming, G. Alexander
    Neutel, Joel
    Homer, Kenneth E.
    Kidron, Miriam
    Rosenstock, Julio
    DIABETES, 2020, 69
  • [40] Empagliflozin Monotherapy Improves Glucose Control in Drug-Naive Patients With Type 2 Diabetes (T2DM)
    Roden, Michael
    Weng, Jianping
    Eilbracht, Jens
    Delafont, Bruno
    Kim, Gabriel
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2013, 62 : A280 - A280
12345